Winfield Associates Inc. cut its position in shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,069 shares of the financial services provider’s stock after selling 425 shares during the period. iShares Nasdaq Biotechnology Index Fund accounts for about 2.6% of Winfield Associates Inc.’s investment portfolio, making the stock its 7th largest position. Winfield Associates Inc.’s holdings in iShares Nasdaq Biotechnology Index Fund were worth $4,673,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of IBB. Tarbox Group Inc. bought a new position in shares of iShares Nasdaq Biotechnology Index Fund during the first quarter worth $104,000. Sei Investments Co. increased its position in shares of iShares Nasdaq Biotechnology Index Fund by 297.0% in the first quarter. Sei Investments Co. now owns 401 shares of the financial services provider’s stock valued at $118,000 after buying an additional 300 shares in the last quarter. Bollard Group LLC increased its position in shares of iShares Nasdaq Biotechnology Index Fund by 0.3% in the second quarter. Bollard Group LLC now owns 392 shares of the financial services provider’s stock valued at $121,000 after buying an additional 1 shares in the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of iShares Nasdaq Biotechnology Index Fund by 174.8% in the first quarter. YorkBridge Wealth Partners LLC now owns 448 shares of the financial services provider’s stock valued at $134,000 after buying an additional 285 shares in the last quarter. Finally, Founders Capital Management acquired a new position in shares of iShares Nasdaq Biotechnology Index Fund during the first quarter valued at approximately $150,000. 64.61% of the stock is currently owned by institutional investors and hedge funds.
Shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ IBB) traded up 0.64% on Friday, reaching $306.41. The company’s stock had a trading volume of 1,155,749 shares. The company’s 50 day moving average is $316.08 and its 200-day moving average is $297.92. iShares Nasdaq Biotechnology Index Fund has a 1-year low of $246.71 and a 1-year high of $329.90.
Separately, Vetr raised iShares Nasdaq Biotechnology Index Fund from a “hold” rating to a “buy” rating and set a $300.66 price target on the stock in a research report on Tuesday, April 18th.
About iShares Nasdaq Biotechnology Index Fund
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.
